Related Experiment Video

Updated: Apr 1, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K

Delivering on the promise: poly ADP ribose polymerase inhibition as targeted anticancer therapy

Geraldine OʼSullivan Coyne1, Alice Chen, Shivaani Kummar

  • 1aDivision of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland bDivision of Medical Oncology, Department of Medicine, Stanford University, Stanford, California, USA.

Current Opinion in Oncology
|October 9, 2015
PubMed
Abstract

Insights

Poly (ADP ribose) polymerase inhibitors (PARPis) show promise for treating BRCA1/2 mutant ovarian and breast cancers. These agents are advancing in clinical trials for various cancer stages and combinations.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Poly (ADP ribose) polymerase inhibitors (PARPis) represent a novel class of anticancer agents.
  • Targeting DNA repair pathways offers a promising strategy in cancer therapy.

Purpose of the Study:

  • To review the rationale, clinical development, and current status of PARPis in oncology.
  • To highlight the therapeutic potential of PARPis in BRCA1/2 mutated cancers.

Main Methods:

  • Review of preclinical data and clinical trial outcomes for PARPis.
  • Analysis of PARPi efficacy as monotherapy and in combination regimens.

Main Results:

  • Olaparib's approval for BRCA1/2 mutated advanced ovarian cancer marks a significant advance.
  • PARPis demonstrate clinical benefit in advanced BRCA1/2 mutant ovarian and breast cancers.

Conclusions:

  • PARPis are effective as single agents and in combination therapies.
  • Ongoing evaluations in neoadjuvant, adjuvant, and metastatic settings underscore their versatility.

More Related Videos

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles09:00

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles

Published on: March 18, 2015

12.2K
Genome-wide Mapping of Drug-DNA Interactions in Cells with COSMIC Crosslinking of Small Molecules to Isolate Chromatin10:05

Genome-wide Mapping of Drug-DNA Interactions in Cells with COSMIC Crosslinking of Small Molecules to Isolate Chromatin

Published on: January 20, 2016

8.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
8.3K
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
109